For example, although bevacizumab has shown promising anti-angiogenic activity, it does not inhibit the interaction between VEGF RTKs and neuropilin-1 (NRPs), which are contributing factors to cancer stem cell survival [197]. The gene discussed is VEGFA; the disease is cancer.